1. There has been an updated ASA practice guideline on neuromuscular
blockade monitoring and reversal. One is encouraging the use of
quantitative monitoring, and another is outlining where sugammadex
can and should be used versus neostigmine. Use of quantitative
monitoring is going to be a dichotomous thing where an institution
either uses or it doesn’t. One of the recommendations in reading the
guidelines is to wait 10 minutes from administration of neostigmine to
extubation. Considering that the pharmacology and the neostigmine
peak effect. is 3 minutes, I have some reservations around it, and it
merits a discussion because this will be a modification of this measure if
we were to track the timing for pass to be when neostigmine is
administered 10 minutes to extubation. The measure does give you an
opportunity to demonstrate a TOF ratio of 0.9 and not give a reversal.
My inclination is to change the measure to look for time of
administration of neostigmine to extubation to determine that it was at
least 10 minutes but do not want to sabotage the measure for anyone. I
am open to keeping the measure as is as an alternative.
g. Coordinating Center review:
1. Analysis of all cases for a month across MPOG last year (October 2024)
showed that across ~8,299 cases where neostigmine was administered
and extubation time documented, the average time between
documentation of neostigmine and extubation was 17 minutes. The
range was between 0 minutes and 22 hours. 23 cases where
documentation (neostigmine and extubation) was at the same time. 16
cases where extubation time was before administration of neostigmine.
This supports that enough variation in data exists to incorporate this
information into a measure. Need discussion about adding this to NMB
02 vs creating a new measure.
2. NMB-02 Measure updates over past year:
1. Updated code to ensure cases would appropriately flag if
reversal was administered after extubation
2. Updated code to ensure cases would appropriately pass if the
acceleromyography ratio of ≥ 0.9 was documented after the last
dose of NMB and before earliest extubation. (Some cases were
being inadvertently excluded).
3. Flowchart and measure result reasons updated
4. Still need to review / validate that new quantitative monitoring concept
values are being included in this measure
h. Discussion:
1. Nirav Shah (MPOG Quality Director): I looked at October 2024 for all
cases across MPOG where neostigmine was administered and had
extubation time documented. There were about 8,000 cases